Occudo Quantitative Strategies’s Recursion Pharmaceuticals RXRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,977	Closed	-$213K	–	1251
2023 Q1	$213K	Buy	+31,977	New	+$254K	0.02%	735
2022 Q4	–	Sell	-48,971	Closed	-$521K	–	1316
2022 Q3	$521K	Sell	48,971 -46,816	-49%	-$474K	0.04%	647
2022 Q2	$780K	Sell	95,787 -23,959	-20%	-$160K	0.06%	467
2022 Q1	$857K	Buy	+119,746	New	+$1.27M	0.07%	432

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Occudo Quantitative Strategies's RXRX Position: Q2 2023 in Review

Occudo Quantitative Strategies sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 31,977 shares — an estimated $213K sold.

Occudo Quantitative Strategies first reported a position in RXRX in Q1 2022 and held it in 4 quarters. The position peaked at $857K in Q1 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

Occudo Quantitative Strategies reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Occudo Quantitative Strategies sold 31,977 Recursion Pharmaceuticals shares in Q2 2023, an estimated $213K.
Occudo Quantitative Strategies first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Occudo Quantitative Strategies's Recursion Pharmaceuticals position peaked at $857K in Q1 2022.
158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.